US FDA clarifies policies on compounding of GLP-1 medicines | Reuters

The FDA just drew a harder line on compounded GLP-1 medications. In a policy clarification issued April 1, the agency made clear that “routine production” of copycat versions of drugs like semaglutide and tirzepatide is not permitted now that national supply shortages have been resolved, as reported by Reuters. Companies that continue producing compounded versions could face enforcement action.

What the FDA Actually Said

The clarification draws a bright line between two very different activities. On one side: legitimate, patient-specific compounding done by state-licensed pharmacies with a valid prescription when a patient’s medical needs can’t be met by the commercially available product. That’s still legal. On the other side: high-volume, standardized production of GLP-1 copies marketed directly to consumers. The FDA is now treating that as unlicensed manufacturing, not compounding.

The distinction matters because it’s the difference between a pharmacist customizing a dose for a specific patient and a company churning out thousands of identical vials to compete with Novo Nordisk’s Ozempic and Wegovy. The FDA has made clear it views the latter as a regulatory violation.

The Backstory

This didn’t come out of nowhere. During the GLP-1 supply crunch of 2023-2024, the FDA allowed compounding pharmacies to produce semaglutide and tirzepatide under shortage provisions. Demand for these weight-loss and diabetes drugs had so far outstripped supply that patients couldn’t get their prescriptions filled. Compounders stepped in to fill the gap.

But the semaglutide shortage officially ended in February 2025, and tirzepatide’s shortage resolution came around the same time. After those shortages ended, companies were supposed to wind down compounded production. Many didn’t. Some ramped up instead.

The situation came to a head in February 2026 when Hims & Hers launched a compounded copy of Novo Nordisk’s oral semaglutide pill. The FDA responded with force:

• Thirty warning letters were sent to compounding operations on February 20, 2026
• The letters targeted misleading advertising, improper comparisons to FDA-approved drugs, and companies implying they compound drugs when they’re actually buying from third parties
• The FDA specifically called out Hims & Hers, signaling it would take “decisive steps” against the company

Hims’ stock dropped more than 4% following the April 1 clarification. The company has since entered an agreement with Novo Nordisk to stop marketing compounded GLP-1s.

What’s Still Allowed

The FDA’s clarification isn’t a blanket ban on all GLP-1 compounding. Here’s what’s still permitted:

• Patient-specific compounding by state-licensed pharmacies under Section 503A, with a valid prescription
• Compounded formulations that differ meaningfully from commercially available products (different dosage strength, route of administration, or a clinically significant modification documented by the prescriber)
• Compounding for patients with documented medical needs that FDA-approved versions can’t address, such as allergies to inactive ingredients

What’s not allowed: mass-marketed, standardized compounded GLP-1s sold through telehealth platforms or direct-to-consumer channels. The FDA views that as drug manufacturing, and it requires full FDA approval.

Why This Matters

If you’re currently getting a compounded GLP-1 from a telehealth company or online pharmacy, your supply could be disrupted. The FDA’s enforcement posture has shifted from warnings to action, and the companies that built businesses around compounded semaglutide and tirzepatide are being forced to change course.

For patients who genuinely need compounded versions (due to dosing requirements or ingredient sensitivities), the pathway still exists through traditional compounding pharmacies with a doctor’s prescription. But the era of easy-access, mass-market compounded GLP-1s appears to be ending.

The bigger picture here is the FDA reasserting control over a market that got away from it during the shortage. Compounding was meant as a safety valve for individual patients, not a loophole for building billion-dollar businesses selling copies of blockbuster drugs. Whether you agree with the FDA’s approach or not, the direction is clear: if you want semaglutide or tirzepatide, the agency wants you getting the FDA-approved versions from Novo Nordisk or Eli Lilly.

Talk to your prescriber now if you’re on a compounded GLP-1. The regulatory window is closing, and having a transition plan beats scrambling when your current source shuts down.